PCI Synthesis (https://www.pcisynthesis.com), headquartered in Newburyport, MA, is a leading contract developer and manufacturer (“CDMO”) of active pharmaceutical ingredients (“APIs”). The Company maintains a full range of API development and manufacturing services for small molecule new chemical entities and niche generic APIs and is uniquely positioned to deliver end-to-end process research and development through commercial scale manufacturing. PCI serves a diverse base of small, mid-size and large global innovator and generic pharmaceutical customers from more than ~75,000 sq. ft. of facilities that are local to Boston, one of the largest and most innovative pharmaceutical hubs in the United States.
The Company has experienced double-digit growth for the past five years and has expanded its capabilities to include GMP manufacturing of nutraceuticals and pharma foods, large-scale cryogenic manufacturing, large-scale chromatography, controlled substance development and medical-grade polymers. PCI’s premier services have earned them numerous awards and recognition as being a top performer amongst its CDMO peers.
Ed Price, the CEO and founder of PCI Synthesis commented: “BlackArch truly understands our business and industry. Their guidance in terms of positioning PCI strategically, operationally and financially to buyers was invaluable and resulted in an exceptional outcome for our Company. They worked tirelessly to execute and close this transaction while securing an ideal partner we are excited to work with.”
BlackArch was retained by PCI synthesis to serve as its exclusive financial advisor given BlackArch’s depth of experience and global reach in the pharmaceutical services sector.
About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass. and is the largest small molecule drug substance manufacturer in the New England area. A wholly-owned subsidiary of Novacap, PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.
Novacap is a global player in pharmaceutical synthesis, advanced specialties and cosmetics. The Group offers its clients custom manufacturing services for pharmaceutical and speciality markets as well as a large portfolio of APIs & pharmaceutical intermediates. Novacap also boasts leading positions in a variety of markets, including cosmetics and fragrances, electronics, home care, food and feed or environment. Novacap sets itself apart not only by the outstanding quality of its products but also by its culture of excellence which aims at providing its clients with the best level of service. Novacap posted sales of $1bn in 2017, operates 28 industrial plants and employs more than 3,000 people across the world.
About BlackArch Partners
BlackArch Partners is a leading middle-market investment bank offering a full spectrum of advisory services to financial sponsors, private companies and diversified corporations. BlackArch addresses the needs of owner-operators, founders and shareholders of private companies with specialized services that include M&A advisory, strategic advisory and private capital solutions. Headquartered in Charlotte, North Carolina, with offices in Chicago, BlackArch features a total of 12 industry-focused practices that cover all sectors of interest to middle-market investors; BlackArch professionals have closed more than 350 transactions in 16 countries on 4 continents. For more information, visit www.blackarchpartners.com.
Securities offered through BlackArch Securities LLC. Member FINRA and SIPC. Testimonials may not be representative of the experience of all clients. Testimonials are not a guarantee of future performance or success.